- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Targeted therapy for HER2 positive breast cancer ; volume:6 ; number:1 ; day:3 ; month:6 ; year:2013 ; pages:1-9 ; date:12.2013
Journal of hematology & oncology ; 6, Heft 1 (3.6.2013), 1-9, 12.2013
- Urheber
-
Incorvati, Jason A.
Shah, Shilpan
Mu, Ying
Lu, Janice
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1756-8722-6-38
- URN
-
urn:nbn:de:101:1-2021082821111792646269
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Incorvati, Jason A.
- Shah, Shilpan
- Mu, Ying
- Lu, Janice
- SpringerLink (Online service)
Ähnliche Objekte (12)
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy
HER2-targeted therapy influences CTC status in metastatic breast cancer
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy
HER2-targeted therapy influences CTC status in metastatic breast cancer
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy
Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer
Trastuzumab-functionalized bionic pyrotinib liposomes for targeted therapy of HER2-positive breast cancer
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases
Differences in axillary response and treatment implications in HER2 positive node positive breast cancer during neoadjuvant HER2 targeted dual therapy
HER2-targeted therapy influences CTC status in metastatic breast cancer
Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy